Expression And Scoring Of HER2/Neu in Variants of Prostate Adenocarcinoma

Santosh Kumar Sidhwani
Madeeha Sadiq
Mubina Lakhani
Summaya Shawana
Raffia Siddiqui
Sobia Hassan
Issue Details
Journal ID1
Volume10
Number3
Year2020
Issue Date2020-09-08 00:00:00
Keywords:
Abstract:
Objective: To evaluate the immunohistochemical expression and scoring of HER2/neu in different variants of adenocarcinoma
of prostate and to compared the association of HER2/neu expression with biological behavior and risk factors of prostate
adenocarcinoma.
Study Design and Setting: Cross sectional study in which all clinically suspected prostate adenocarcinoma cases received
at the laboratory Saddar Karachi during the years 2015 and 2016 were evaluated for morphological features of adenocarcinoma.
Methodology: This cross sectional study was carried out using prostate biopsies of clinically suspected prostate
adenocarcinoma. The diagnosis of adenocarcinoma was confirmed and histological characterization was done by evaluating
the morphological features. The tumors were graded according to the revised 2015 Gleason’s grouping. Immunohistochemical
analysis for HER2/neu expression was performed in the most representative tumor block. SPSS version 22 was used for
data analysis. Mean frequency and percentages were calculated for quantitative variables, whereas chi-square test and
Fisher’s Exact Test were applied for qualitative variables. P-value of < 0.05 was considered as significant.
Results: Out of 77 biopsies only one showed moderate HER2/neu expression. Positive HER2/neu was acinar variant. No
significant statistical association was observed between expression of HER2/neu and prostate cancer variants. The positive
case had age more than 60 years with moderately increased serum PSA levels and was aggressive in nature at the time of
diagnosis.
Conclusion: It was concluded from the study that HER2/neu was rarely expressed in prostate adenocarcinoma.

Published: 2021-03-18

Last Modified: 2022-02-21 00:16:21